A comprehensive imaging biomarker-based diagnostic workup in patients with neurodegenerative diseases may include FDG-PET, as well as β-amyloid-PET and tau-PET, for a classification within the A/T/N scheme, namely, amyloid-PET or CSF β-amyloid (A), CSF p-tau (T), and MRI-based medial temporal lobe atrophy (N) [7]. The gene discussed is MAPT; the disease is neurodegenerative disease.